Reuters, December 29, 2011. With the scandal surrounding France’s Poly Implant Prothese (PIP), questions arise whether there should be a national or worldwide breast implant registry.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
With Doubts, FDA Panel Votes for Yaz and Related Contraceptives
National Public Radio, December 9, 2011. Doubts have been growing about Yasmin, Yaz and their sister contraceptives for several years now. And those doubts reached full flower at a Food Drug Administration advisory panel on Thursday.
Read More »Labels for Some Birth Control May Require Stronger Wording
WBALTV, December 9, 2011. Experts said the new generation of birth control pills, like Yaz and Yasmine, contain a new type of hormone called drospirenone, and several studies have suggested that women who take these types of birth control pills have twice the risk for developing blood clots compared to those taking older forms of pills.
Read More »FDA Panel Gives Tepid Okay to Birth Control Pill
Medpage Today, December 9, 2011. In a lukewarm endorsement, an FDA advisory panel voted 15-11 that the benefits of controversial drospirenone-containing oral contraceptives outweigh the risk of venous thromboembolism.
Read More »FDA Revokes Avastin Approval for Breast Cancer- Decision Leaves Some Devastated
The Washington Post, November 19, 2011. “The science is clear: Breast cancer patients are more likely to be harmed than helped by Avastin,” said Diana Zuckerman, president of the National Research Center for Women & Families. “The risks of the drug are very substantial and can be fatal, killing patients long before they would otherwise die from the disease. FDA made a scientific decision, and it was absolutely the right decision.”
Read More »